RT Journal Article
SR Electronic
T1 Interpretation of breast cancer screening guideline for Chinese women
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 825
OP 835
DO 10.20892/j.issn.2095-3941.2019.0322
VO 16
IS 4
A1 Huang, Yubei
A1 Tong, Zhongsheng
A1 Chen, Kexin
A1 Wang, Ying
A1 Liu, Peifang
A1 Gu, Lin
A1 Liu, Juntian
A1 Yu, Jinpu
A1 Song, Fengju
A1 Zhao, Wenhua
A1 Shi, Yehui
A1 Li, Hui
A1 Xiao, Huaiyuan
A1 Hao, Xishan
YR 2019
UL http://www.cancerbiomed.org/content/16/4/825.abstract
AB Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women. It is imperative to develop breast cancer screening guideline that is suitable for Chinese women. By summarizing the current evidence on breast cancer screening in Chinese women, and referring to the latest guidelines and consensus on breast cancer screening in Europe, the United States, and East Asia, the China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) have formulated population-based guideline for breast cancer screening in Chinese women. The guideline provides recommendations on breast cancer screening for Chinese women at average or high risk of breast cancer according to the following three aspects: age of screening, screening methods, and screening interval. This article provides more detailed information to support the recommendations in this guideline and to provide more direction for current breast cancer screening practices in China.